Axicabtagene Ciloleucel

Disease:  Large B-cell Lymphoma

Indication:  Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

Company:  Kite Pharma

Private Company

Notable Transactions:  Gilead acquired Kite Pharma for $12B

Methods:  The patient sits for leukapheresis, and the product is sent to a lab. There, the T cells are genetically enhanced to attack cancerous cells and expanded.

Link to the clinical trial:  NCT02348216

Current Phase:  FDA Approved

Subscribe to Our Newsletter

Subscribe to our newsletter to keep up to date with all the latest news about AGT!

[formidable id=9]

Follow AGT on Social Media